Ozempic, Wegovy, other GLP-1RA drugs not linked to increased pancreatic cancer risk, study finds
Posted:
New research has concluded that drugs from the glucagon-like peptide-1 receptor agonists (GLP-1RA) class do not increase the risk of pancreatic cancer.
Researchers have begun scanning the first young athletes taking part in a new study using advanced brain imaging to explore the effects of head injuries in 11 to 18-year-olds.
Read more here.
The Swiss company’s over-the-counter wrist wearable, which uses optical sensors to gather blood pressure readings, will be available to U.S. consumers in 2026.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us